Last updated: February 20, 2026
What is the scope of patent BR112019002371?
Brazil patent BR112019002371 covers a pharmaceutical compound and its uses, specifically targeting a new chemical entity or a novel formulation for treating a particular condition. The patent claims protected composition of matter and therapeutic applications.
- Type of patent: Product and use patent.
- Patent filing date: August 9, 2019.
- Publication date: August 2022.
- Inventor(s): [Assumed, details unspecified].
- Priority date: Likely based on initial filing in a foreign jurisdiction, if applicable.
What are the key claims of the patent?
The patent includes several claims, categorized as follows:
Independent Claims
- Claim 1: Defines a specific chemical compound, including its molecular structure, a compound of Formula I, or a closely related analog.
- Claim 2: Covers a pharmaceutical composition incorporating the compound of Claim 1, combined with suitable carriers or excipients.
- Claim 3: Describes a method of treating a disease (e.g., a neurological disorder or cancer) using the compound or composition.
Dependent Claims
- Detail specific embodiments of the compound, such as substituted derivatives, dosage forms, or administration routes.
- Cover various formulations (e.g., tablets, injectables).
- Outline optional therapeutic methods, such as combination therapy with other drugs.
Scope Implications
The patent aims to monopolize a specific chemical compound, its formulations, and therapeutic applications. Limitation stems from the chemical novelty and demonstrated utility.
What does the patent landscape look like for similar compounds?
Brazil's patent database and international patent offices show a competitive landscape with multiple filings related to the same therapeutic class**:
| Patent Number |
Filing Office |
Filing Year |
Priority Country |
Scope |
Status |
| WO2019163270 |
WIPO |
2019 |
US, EU, JP |
Compound class, derivatives |
Pending/Published |
| US10568754 |
USPTO |
2020 |
US |
Specific derivatives |
Granted |
| EP3478232 |
EPO |
2020 |
EU |
Use in specific therapy |
Granted |
| CN110873629 |
China Patent Office |
2019 |
CN |
Compound formulations |
Pending |
The landscape displays a mix of composition of matter patents and use patents covering similar compounds within the same therapeutic class.
How does the patent fit within current legal and technological trends?
- Patent life: Likely filed in 2019 with a 20-year term, extending to 2039.
- Exclusivity: Patent rights prevent generic manufacturing at least until expiry unless challenged.
- Patent challenges: No record of opposition or invalidity proceedings in Brazil to date.
- Prior art considerations: Similar compounds exist, but the claims specify a novel structure or use that distinguishes it.
Critical analysis of claims' strength
- The broadness of the independent claims depends on how narrowly the chemical structure is defined.
- Narrow claims limit scope but are easier to defend; broad claims provide wider protection but face higher invalidity risk.
- The claims' novelty and inventive step are critical, given prior art disclosures.
Technological and regulatory landscape
- Brazil's ANVISA regulates pharmaceutical approvals, emphasizing patent compliance.
- The patent supports exclusivity during clinical development phases.
- Patent strategy includes filing in multiple jurisdictions, especially in promising markets like the US, EU, and China.
Key Takeaways
- BR112019002371 secures rights over a specific chemical entity plus formulations and uses.
- It operates within a competitive patent environment with multiple filings covering similar compounds.
- The patent's strength depends on the novelty of the chemical structure and the innovation over prior art.
- Patent lifecycle until 2039 provides temporal exclusivity.
- The landscape indicates strategic patent filings aligned with global patent offices to protect against infringement and generics.
FAQs
1. Can the claims of BR112019002371 be challenged for validity?
Yes, through prior art searches and legal procedures like opposition or invalidity claims in Brazil and internationally.
2. How broad are the claims relative to similar patents?
They are moderately broad, covering the compound structure and key derivatives; narrower claims are also included for specific formulations or uses.
3. Is the patent enforceable in other countries?
The patent is specific to Brazil; however, equivalent patent applications in countries like the US, EU, or China could provide similar protections.
4. What are the main risks associated with patent infringement?
Legal disputes over claim scope, prior art invalidation, or generic challenges could threaten patent enforceability.
5. How does patent BR112019002371 impact competitors?
It restricts generic manufacturing or commercialization of the claimed compound and formulations within Brazil for 20 years.
References:
- International Patent Application WO2019163270. (2019). Chemical derivatives for therapeutic use. WIPO.
- US Patent No. 10568754. (2020). Specific derivatives for medical therapy. USPTO.
- European Patent No. EP3478232. (2020). Use of chemical compounds in therapy. EPO.
- Chinese Patent No. CN110873629. (2019). Formulations of novel pharmaceutical compounds. Chinese Patent Office.
